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ABSTRACT
Health-related quality of life (HRQoL) is a broad concept reﬂecting a patient’s general subjective
perception of the effect of an illness or intervention on physical, psychological and social aspects
of their daily life. HRQoL among patients infected with HIV has become an important indicator of
impact of disease and treatment outcomes. A cross-sectional survey was carried out at
Chitungwiza Central Hospital, Zimbabwe, to assess HRQoL in patients with HIV/AIDS receiving
antiretroviral therapy (ART), using two validated instruments. The HIV/AIDS-targeted quality of
life (HAT-QoL) and EuroQoL Five-dimensions-Three-level (EQ-5D-3L) instruments were used to
assess HRQoL. Internal consistency reliability and convergent validity of the two instruments
were also evaluated. For construct validity, the relationships between HRQoL scores and socio-
economic and HIV/AIDS-related characteristics were explored. The median scores for the HAT-
QoL dimensions ranged from 33.3 (ﬁnancial worries) to 100 (HIV mastery). A considerably low
HAT-QoL dimension score of 50.0 was observed for sexual function. There were ceiling effects for
all HAT-QoL dimension scores except for ﬁnancial worries and disclosure worries. Floor effects
were observed for ﬁnancial worries and sexual function. The median of the EQ-5D-3L index and
visual analogue scale (VAS) was 0.81 and 79.0, respectively. There were no ﬂoor or ceiling effects
for both the EQ-5D-3L index and VAS. The overall scale Cronbach’s alpha was 0.83 for HAT-Qol
and 0.67 for EQ-5D-3L. HAT-QoL demonstrated good convergent validity with EQ-5D index (0.58)
and VAS (0.40). A higher level of HRQoL was positively and signiﬁcantly related to income,
education and employment. The patients’ self-reported HRQoL was generally satisfactory in all
the HAT-QoL dimensions as well as the two components on the EQ-5D-3L instrument. The two
instruments demonstrated good measurement properties in HIV/AIDS patients receiving ART and
have potential for use, alongside biomarkers, in monitoring outcomes of interventions.
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The World Health Organization (WHO) deﬁnes health
as “a state of complete physical, mental and social well-
being and not merely the absence of disease or inﬁrmity”
(WHO, 1946). This all-encompassing deﬁnition implies
the importance of capturing effect changes both in
terms of life expectancy and quality of life (QoL), and
led to the development of the concept of health-related
quality of life (HRQoL). HRQoL is a multidimensional
concept reﬂecting an individual’s perception on how
an illness or intervention affects the physical, psychologi-
cal and social aspects of his or her health (European
Medicines Agency, 2005; Polinder, Haagsma, van Klave-
ren, Steyerberg, & van Beeck, 2015; Revicki, 1989).
HRQoL measures are becoming an integral part of
patient follow-up, providing valuable feedback, from
the patients’ perspective, about the disease and associ-
ated interventions.
HRQoL assessment in HIV/AIDS takes into account
the impact of the infection and antiretroviral therapy
(ART) on an individual’s physical, psychological and
social well-being, as reported by the patient. HRQoL
measures are important as indicators of the effectiveness
of HIV/AIDS treatment and care programmes. Measure-
ments of HRQoL can be incorporated into models that
inform economic evaluation of HIV/AIDS treatment ser-
vices, making them pivotal in resource allocation
decisions (Feeny, 2000; Robberstad & Olsen, 2010).
Such assessments can also be useful in identifying factors
associated with HRQoL among people living with HIV,
thereby informing public health decisions on speciﬁc
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impact mitigation and support interventions that may be
required to maximize HRQoL (Degroote, Vogelaers, &
Vandijck, 2014; Mutabazi-Mwesigire, Katamba, Martin,
Seeley, & Wu, 2015).
HIV remains a major public health problem in Zim-
babwe, with an adult prevalence of 14.7% (UNAIDS,
2013) and is associated with an estimated 64,000
AIDS-related deaths annually (UN Joint Programme
on HIV/AIDS (UNAIDS), 2014). The ART programme
in Zimbabwe was formally started in April 2004 with
the objective of reducing morbidity and mortality due
to HIV and AIDS, and improving the QoL for people liv-
ing with HIV (Apollo et al., 2010). Programme scale-up
efforts resulted in increased access to ART. A few studies
have assessed HRQoL as an outcome in patients living
with HIV/AIDS in Zimbabwe (Patel et al., 2009; Sebit
et al., 2000; Taylor, Dolezal, Tross, & Holmes, 2008,
2009). However, none of these studies used a generic
and a disease-targeted instrument simultaneously. The
simultaneous use of a generic and disease-targeted
instrument for assessing QoL in a disease-speciﬁc popu-
lation is highly recommended since this approach is
thought to provide a comprehensive assessment and
measurement of disease-speciﬁc QoL (Holmes & Shea,
1999; Patrick & Deyo, 1989). Although the 2010 WHO
guidelines for ART recommended that countries reduce
the use of stavudine (d4T) because of its well-recognized
toxicity, the process of phasing it out has been slow in
most treatment centres in Zimbabwe. An assessment of
HRQoL in patients receiving ART was therefore necess-
ary. The purpose of this study was to assess HRQoL in
patients with HIV/AIDS receiving ART at a central hos-
pital in Zimbabwe, using two validated instruments. In
addition, measurement properties of the two instru-
ments were assessed in order to ascertain if they were
still feasible and valid methods of HRQoL assessments
in the era of improved ART availability in Zimbabwe.
Methods
Participants and setting
A cross-sectional descriptive study was conducted at
Chitungwiza Central Hospital, during the period July–
October 2013. The hospital is one of the ﬁve major refer-
ral hospitals in Zimbabwe, located about 30 km South
East of Harare. The Opportunistic Infections clinic pro-
vides ART and care to approximately 8000 HIV-positive
patients. The sample size was estimated using Pocock’s
formula for single mean. Using EQ-5D scores reported
in a study conducted in a similar population in South
Africa (Gow, George, & Govender, 2013), a signiﬁcance
level of 5%, a population standard deviation (σ) of 20 and
an interval around the mean (d) of 2.5, a sample size of
246 was estimated. Assuming a response rate of 70%, 350
participants were targeted. Patients with HIV/AIDS,
aged 18–60 years and receiving ART were randomly
selected and invited to participate during their clinic vis-
its. During the study period, treatment guidelines rec-
ommended initiation of ART in all patients presenting
with WHO stages 3 and 4 of HIV disease regardless of
the CD4 count. In cases where CD4 count was available,
initiation of ART in all adults and adolescents, including
pregnant women, with CD4 cell counts of less than 350
cells/mm3, was recommended.
Measures
HRQoL was measured using the HIV/AIDS-Targeted
Quality of Life (HAT-QoL) and EuroQoL Five-dimen-
sions-Three-level (EQ-5D-3L) instruments, which have
previously been used and validated in Zimbabwean
populations (Jelsma et al., 2001; Rabin & de Charro,
2001; Taylor, Dolezal, Tross, & Holmes, 2009). The
Shona version of the HAT-QoL questionnaire was
adapted from Taylor et al. (2009). The modiﬁcation
was the inclusion of the sexual function dimension.
The Shona version of the EQ-5D-3L was obtained
from the EuroQoL group (Rabin & de Charro, 2001).
The EQ-5D-3L was used to measure HRQoL in two
parts. The ﬁrst part consisted of ﬁve dimensions: mobi-
lity, self-care, usual activities, pain/discomfort and
anxiety/depression. The second part was a visual ana-
logue scale (VAS) ranging from 0 to 100, from which
participants were asked to estimate their QoL score. A
separate demographics questionnaire was used to gather
information on socio-demographic and HIV/AIDS-
related characteristics.
Procedures and outcomes
Three trained health-care workers (off-duty) gathered
information using face-to-face interviews. The main out-
come measure was HRQoL. The independent variables
were the socio-demographic characteristics, obtained at
the time of enrolment; and the clinical characteristics,
obtained from the participants’ medical charts recorded
within the preceding three months from the date of their
participation in the study.
Ethical approval
Ethical approval was obtained from the Joint Parire-
nyatwa Hospital and College of Health Sciences Ethical
Committee (JREC 194/13), the Medical Research Coun-
cil of Zimbabwe (MRCZ/B/564) and the Chitungwiza
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Central Hospital institutional ethics committee. All par-
ticipants provided written informed consent.
Statistical analysis
Data analysis was performed using Stata Version 13.0
(College Station, Texas). Descriptive analysis was used
to summarize the socio-demographics and HIV-related
characteristics, and HRQoL proﬁles of the participants.
Reponses from the HAT-QoL instrument were trans-
formed to numerical values for each dimension using
the guide provided with the instrument (Holmes &
Shea, 1998). The ﬁnal dimension score was a linear
scale, ranging 0–100, where 0 was the worst score poss-
ible and 100 was the best score possible. The health states
on the EQ-5D-3L were transformed into an index value
using the guideline provided by the developers of the
instrument (Rabin & de Charro, 2001). The EQ-5D
health states were converted to a single summary index
for each participant using value sets for Zimbabwe
(Jelsma, Hansen, De Weerdt, De Cock, & Kind, 2003).
Dimension-speciﬁc psychometric evaluations were
completed, including corrected item-total correlations
and internal consistency reliability coefﬁcients and ﬂoor/
ceiling effects. The internal consistency reliability was
determined for each of the instruments using Cronbach’s
alpha, with a value of greater than or equal to 0.70 con-
sidered adequate (Cronbach, 1951; McCrae, Kurtz, Yama-
gata, & Terracciano, 2011; Tavakol & Dennick, 2011).
Corrected item-total correlations were used to observe
the reliability of individual items. For each item’s total
score, a correlation of 0.40 was considered acceptable.
Floor/ceiling effects were considered to be present when
the percentage of participants with the lowest (ﬂoor) or
highest (ceiling) possible score was more than or equal
to 20% (Holmes & Shea, 1998; Taylor et al., 2009).
Construct validity assessments were done using the
socio-demographic and HIV-related characteristics.
The variables were dichotomized, and subgroup median
dimension scores were compared. Differences between
median HRQoL scores of various patient groups were
evaluated using the Mann–Whitney U-test. Convergent
validity between the EQ-5D-3L index/VAS and the
HAT-QoL dimensions was assessed using Spearman
rank order coefﬁcients (Spearman’s ρ), including a
comparison with the HAT-QoL summary score. The
HAT-QoL summary score was calculated by averaging
the dimension scores. Correlation coefﬁcients less
than or equal to 0.30 were considered negligible,
0.31–0.50 as low, 0.51–0.75 as moderate and above
0.75 as high (Mukaka, 2012). Unless, otherwise indi-





A total of 257 out of the targeted 350 patients (73.4%
response rate) consented and participated. Character-
istics of the patients who declined to participate and
reasons for non-participation could not be established.
The majority of the participants were female (72.0%),
with a mean age of 39.7 years (SD; 8.9). The majority
of participants (42.8%) were in HIV stage III. The
median CD4 count was 343 cells/mm3 (range 8–1431).
About half of the participants were on stavudine-based
ART (49.1%), while 38.9% were on a tenofovir-based
regimen and 12.0% were on a zidovudine-based regimen.
The median time on ART was 24 months (range 1–144).
The socio-demographic and HIV/AIDS-related charac-
teristics of the participants of the study are summarized
in Table 1.
HRQoL score descriptions and psychometric
properties
The HAT-QoL dimension, EQ-5D index and VAS scores
are summarized in Table 2. The median scores for the
HAT-QoL dimensions ranged from 33.3 (ﬁnancial wor-
ries) to 100 (HIV mastery). There were ceiling effects for
all HAT-QoL dimensions except for ﬁnancial and dis-
closure worries. Floor effects were observed for ﬁnancial
worries and sexual function. The Cronbach’s alpha of all
the HAT-QoL dimensions was 0.83. All Cronbach’s
alphas for the HAT-QoL dimensions were robust
(≥0.70). Only two items (disclosure worries: 0.38 and
provider trust: 0.32) did not reach the recommended
item-total correlation coefﬁcient threshold of 0.40. The
median scores for the EQ-5D-3L index and VAS were
0.81 and 79.0, respectively. There were no ﬂoor/ceiling
effects for the two EQ-5D-3L components. Cronbach’s
alpha of ﬁve dimensions of the EQ-5D-3L was 0.67.
Construct validity
Statistically signiﬁcant median score differences for HA-
QoL dimensions, EQ-5D-3L index and VAS across par-
ticipant subgroups are presented in Table 3. A complete
proﬁle for HRQoL of different participant groups and
discriminative validity of the instruments is presented
in Appendix 1. Statistically signiﬁcant relationships
were observed consistently between independent vari-
ables and three HAT-QoL dimensions (health worries,
ﬁnancial worries and sexual function). Male participants
were less likely to have ﬁnancial worries and more likely
to have worse sexual function. Younger subjects were
more likely to have worse sexual function, health and
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disclosure worries, and less likely to have HIV mastery.
Participants earning less than US$250 per month indi-
cated worse overall function and were more likely to
have health and ﬁnancial worries. Statistically signiﬁcant
relationships were consistently observed between the
EQ-5D-3L index and VAS scores, and level of education,
employment status and income subgroups. Participants
with primary level education, unemployed and a
monthly income of less than US$250 were more likely
to have poor QoL on the EQ-5D-3L index and VAS.
Convergent validity
Convergent validity of the HAT-QoL dimensions with
EQ-5D-3L components was demonstrated and the data
are presented in Table 4. All Spearman rank order coef-
ﬁcients for EQ-5D index and VAS comparisons with the
HAT-QoL dimensions were signiﬁcant (p < .01) except
for the one between VAS and disclosure worries (ρ
= .12; p = .06). Correlations for EQ-5D index compari-
sons with HAT-QoL dimensions were negligible with
disclosure worries and provider trust; low with life satis-
faction, ﬁnancial worries, medication worries, HIV mas-
tery and sexual function; and moderate with the overall
function and health worries. Correlations for VAS com-
parisons with HAT-QoL dimensions were negligible
with HIV mastery, disclosure worries, provider trust
and sexual function; low with life satisfaction, health
worries, ﬁnancial worries and medication worries; and
moderate with the overall function. The coefﬁcient
between EQ-5D index and VAS was 0.59 (p < .001).
The coefﬁcients for EQ-5D index and VAS comparisons
with the HAT-QoL summary score were 0.58 and 0.40,
respectively (p < .001).
Table 1. Socio-demographic and clinical characteristics of the















































Table 2. QoL score distributions and internal consistency reliability coefﬁcients.
HAT-QoL domain scores EQ-5D-3L
OVFXN LISAT HEAWO FINWO MEDWO HIVMA DISWO PROTR SXFXN EQIND VAS
Range 0–100 0–100 0–100 0–100 0–100 0–100 0–100 0–100 0–100 0.23–0.9 20–100
Median 87.5 81.2 87.5 33.3 95 100 70 75 50 0.81 79
Mean 77.0 74.4 79.4 40.6 86.7 74.9 64.4 68.4 47.0 0.77 73.3
SD 24.8 28.8 25.2 32.9 19.9 37.8 30.1 32.4 40.2 0.15 18.9
Kurtosis 3.14 3.10 3.67 2.04 6.51 2.70 2.41 2.33 1.50 5.62 1.94
Skewness −0.99 −1.01 −1.25 0.39 −1.91 −1.04 −0.67 −0.71 0.19 −1.76 −0.28
% ﬂoora 1 4 1 22 0 8 7 8 30 0 0
% ceilinga 29 39 40 11 49 56 18 36 30 0 8
Reliabilityb 0.81 0.81 0.79 0.82 0.81 0.81 0.83 0.84 0.83 0.67 –
Domain-total correlation
coefﬁcient
0.65 0.58 0.78 0.51 0.60 0.61 0.38 0.32 0.45 – –
Number of subjects 257 257 257 257 257 257 257 257 257 257 256
Notes: Dimensions for the HAT-QoL include the overall function (OVFXN), life satisfaction (LISAT), health worries (HEAWO), ﬁnancial worries (FINWO), medication
worries (MEDWO), HIV mastery (HIVMA), disclosure worries (DISWO), and provider trust (PROTR). QoL scores from the EQ-5D-3L include EQ-5D Index (EQIND)
and visual analogue scale (VAS).
aThe proportion of subjects scoring the bottom-most and top-most score for a dimension.
bRefers to internal consistency reliability as represented by Cronbach’s alpha coefﬁcients.
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Discussion
To our knowledge, this is the ﬁrst attempt to assess the
HRQoL using a generic and an HIV-targeted instrument
simultaneously in patients living with HIV/AIDS in
Zimbabwe. Participants in this study reported high
QoL, which may be a direct result of ART. The
HRQoL scores for the EQ-5D-3L are similar to those
reported in patients living with HIV receiving ART in
other countries (Grossman, Sullivan, & Wu, 2003; Lou-
wagie et al., 2007; Nglazi, West, Dave, Levitt, & Lambert,
2014). No similar study assessing HRQoL using the EQ-
5D-3L in HIV patients receiving ART was found for
Zimbabwe. The HAT-QoL dimension scores were con-
siderably higher compared to previously reported values
for people living with HIV/AIDS in Zimbabwe, where
dimension mean scores were 40.2–79.3 (Taylor et al.,
2008) in 2001 and 31.4–74.8 (Taylor et al., 2009) in
2002. The differences in time horizons during which
data were collected may explain these differences. The
ART programme in Zimbabwe resulted in the wide-
spread availability of antiretroviral drugs which might
explain the higher HRQoL in this study. The previous
studies recruited patients as they presented for treatment
for HIV-related opportunistic infections, with the
majority meeting the WHO case deﬁnition for AIDS.
In contrast, less than half of the patients in the current
study were classiﬁed into the AIDS stage. The current
study was performed in an urban setting whilst the two
previous studies were carried out in a rural setting
where patients relied on traditional medical practitioners
to a greater extent.
HAT-QoL showed good internal reliability consistency
in all the dimensions, further afﬁrming the validity of the
instrument in a Zimbabwean setting (Taylor et al., 2009).
This is particularly important considering the socio-cul-
tural sensitivities associated with QoL instruments.
The Cronbach’s alpha for the EQ-5D-3L domains of
0.67 was slightly lower than the threshold value of
0.70. However, the item-test correlations (not shown)
were higher than the threshold value of 0.40, thus ren-
dering reliability satisfactory. The lack of ﬂoor/ceiling
effects on EQ-5D index and VAS further demonstrates
the validity of the EQ-5D-3L instrument in assessing
the HRQoL in HIV-positive patients receiving ART.
Further assessments may be required to conﬁrm this
ﬁnding, since the EQ-5D-3L has been associated with
substantial ﬂoor/ceiling effects when used in the general
population as well as in patients living with HIV (Badia,
Schiafﬁno, Alonso, & Herdman, 1998; Bharmal & Tho-
mas, 2006; Johnson & Pickard, 2000; Sakthong, Schom-
mer, Gross, Prasithsirikul, & Sakulbumrungsil, 2009;
Wang, Kindig, & Mullahy, 2005; Wu et al., 2002).
Signiﬁcant relationships between HRQoL and partici-
pants’ monthly income were consistently found across
the majority of the HAT-QoL dimensions and the two
components of the EQ-5D-3L. The positive correlation
Table 3. Construct validity assessment of HRQoL tools using socio-demographic and clinical variables.
Characteristics HAT-QoL domains EQ-5D-3L scores
OVFXN LISAT HEAWO FINWO MEDWO HIVMA DISWO PROTR SXFXN EQIND VAS
Gender
Male vs. Female –§ – – 16.7* – – – – 25** – –
Age
<30 vs. >=30 – – −18.8* – – −25* −25** – −50* – –
Marital status
Married vs. other (Single+ Widowed+
Divorced)
– – – – – – – – 25* 0.046** –
Level of education
Primary vs. other (Secondary+ Tertiary) – – – −8.4** – – – – −25* −0.046** −10**
Employment status
Employed vs. Unemployed – 21.9** 12.5* – – – – – – 0.067** 19*
ART regimen
d4t-based vs. other (AZT-based+ TDF-
based)
– – – – 5** – – −16.6* – – –
Income (USD)
<250 vs. >250) −12.5** −25** −12.5** −33.4** – 0* – – 0* −0.057** −19**
Time on ART (months)
<12 vs. >=12 – – – – – – – – – 0.067* –
Notes: Dimensions for the HAT-QoL include the overall function (OVFXN), life satisfaction (LISAT), health worries (HEAWO), ﬁnancial worries (FINWO), medication
worries (MEDWO), HIV mastery (HIVMA), disclosure worries (DISWO) and provider trust (PROTR). QoL scores from the EQ-5D-3L include EQ-5D Index (EQIND) and
visual analogue scale (VAS). AZT = zidovudine, d4T = stavudine, TDF = tenofovir disoproxil fumarate
Subgroup median score differences are presented. Median score differences were computed by subtracting the median score for the second subgroup in each
parenthetical clause from the median score for the ﬁrst subgroup (e.g. median score for females from that for males). A negative sign indicates worse function,
more worries, less satisfaction, and so on, in the ﬁrst subgroup in the parenthetical clause; a positive sign indicates better function, fewer worries, more sat-
isfaction, and so on, by the ﬁrst subgroup.
*Differences are signiﬁcant at p < .05 but > .01.
**Differences are signiﬁcant at p < .01.
§Cells with a “–” indicate that the difference in subgroup mean scores has a p-value > .05.
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between income and HRQoL scores was also reported in
other settings (Campsmith, Nakashima, & Davidson,
2003; Jelsma & Ferguson, 2004; Stangl, Wamai, Mermin,
Awor, & Bunnell, 2007). This demonstrates that, even
though services such as CD4 count test, viral load test
and ART are provided for free in public health pro-
grammes, patients may still require ﬁnancial resources
to access other health-care services. Failure to access
any of these services may have a negative impact on
the QoL of patients. Consistent with other studies, edu-
cation and employment, which are closely related to
income, showed signiﬁcant relationships with HRQoL
(Jelsma & Ferguson, 2004; Louwagie et al., 2007; Nglazi
et al., 2014). Gender, age and marital status also had sig-
niﬁcant relationships with HRQoL. Higher QoL scores
observed in male participants may be related to the cul-
tural norms and expectations within the Zimbabwean
society about the roles and responsibilities that are
deemed appropriate for men and women (Oparah,
Soni, Arinze, & Chiazor, 2013).
The health status of participants as assessed by CD4
cell counts andWHO clinical stages was not signiﬁcantly
related toHRQoL. Similar assessments of the relationship
between CD4 cell counts and HRQoL in Africa reported
weak correlations (Igumbor, Stewart, & Holzemer, 2013),
while other studies observed signiﬁcant correlations
(Bhargava & Booysen Fle, 2010; Nglazi et al., 2014; Ven-
ter, Gericke, & Bekker, 2009). The relatively small sample
size in our study, and the large proportion of missing data
(30%) in both the CD4 count and WHO stage variables,
may have limited the power for detecting relationships
between the clinical levels and HRQoL scores.
The current study draws major strength from the use
of generic and HIV-targeted instruments, allowing for a
comprehensive assessment of HRQoL. The Shona ver-
sions of the HAT-QoL and EQ-5D-3L instruments
were culturally adopted and validated for the Zimbab-
wean population, making their use in this study appro-
priate. Furthermore, the availability of value sets for
Zimbabwe allowed the derivation of the EQ-5D-3L
index values weighted by tariffs from the same popu-
lation. This study has several potential limitations that
are important to consider for future research. Partici-
pants were selected from a single, urban facility, thus
limiting the generalizability of ﬁndings. The extrapol-
ation of the ﬁndings to other settings requires caution
considering that HRQoL is sensitive to socio-cultural
factors. The high HRQoL might be as a result of survi-
vorship bias, where only patients with high QoL, who
regularly come to the health-care facility for their fol-
low-up visits and antiretroviral pick-ups, were included
in the study. Patients with low HRQoL might have
declined participation, stayed at home, became lost-to-
follow up or died due to HIV/AIDS-related causes.
Patients declining participation may have had advanced
HIV/AIDS or had not mastered living with the disease,
hence were not comfortable talking about their con-
dition. The use of health-care workers as interviewers
could have resulted in participants reporting higher
HRQoL. The cross-sectional design of the study did
not allow for assessment of HRQoL over time. Following
up the participants over at least a year would have pro-
vided valuable data of the relationship of the change in
clinical biomarkers and changes in HRQoL scores. In
addition, causality could not be inferred between any
of the independent variables described and HRQoL
due to the cross-sectional design of the study.
Conclusions
The level of HRQoL observed in this study was generally
high. Income, education and employment were posi-
tively and signiﬁcantly associated with HRQoL. Inter-
ventions that improve the socio-economic situation in
the country will enhance the QoL of HIV-infected
patients receiving ART.
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Appendix 1. Construct validity assessment of HRQoL tools using socio-demographic and clinical
variables.
HAT-QoL domain median scores
EQ-5D-3L Median
Scores
Variables OVFXN LISAT HEAWO FINWO MEDWO HIVMA DISWO PROTR SXFXN EQIND VAS
Gender
Male 87.5 87.3 87.5 50.0* 95 100 75 79.2 50** 0.83 77
Female 87.5 81.5 87.5 33.3 100 100 70 75 25 0.79 79
Age
<25 93.8 87.5 87.5 70.8 95 100 60 87.5 0 0.76 65
25–54 87.5 81.2 87.5 33.3 95 100 70 75 50 0.83 79
>54 79.2 100 90.6 37.5 92.5 100 77.5 91.7 75 0.79 64.5
Marital status
Single 70.8 75 93.8 50 95 75 70 83.3 0 0.79 70
Married 87.5 87.5 87.5 33.3 100 100 70 75 50 0.83 80
Widowed 83.3 81.2 93.8 41.7 95 100 80 33.3 25 0.79 70
Divorced 85.4 75 84.4 25 90 56.3 75 70.8 25 0.79 70
Level of education
Primary 79.2* 81.3 87.5 33.3* 95 100 75 83.3 25* 0.79** 70**
Secondary 91.7 87.5 87.5 41.7 100 100 70 75 50 0.83 79.5
Tertiary 100 87.5 100 50 100 100 90 50 75 0.85 99
Employment status
Employed 91.7 100* 100* 50 100 87.5 80 75 50 0.79** 89
Unemployed 83.3 78.1 87.5 33.3 95 100 70 75 50 0.85 70
Accommodation
Owned 87.5 87.5 90.6 41.7 95 100 75 75 50 0.81 77
Rented 83.3 75 87.5 33.3 100 100 70 83.3 50 0.81 79
ART regimen
d4t-based 87.5 87.5 87.5 50 90** 100 70 75* 50 0.78 72
AZT-based 91.7 75 87.5 25 100 100 70 75 50 0.83 80
TDF-based 83.3 87.5 100 45.8 100 100 75 58.3 50 0.83 79
Missing 83.3 75 87.5 33.3 95 87.5 70 83.3 50 0.79 70
WHO clinical
staging
I 91.7 87.5 93.8 41.5 95 100 65 83.3 25 0.83 80
II 83.3 87.5 87.5 33.3 95 100 80 83.3 50 0.80 70
III 87.5 81.3 93.8 50 97.5 100 75 66.7 50 0.83 80
Missing 83.3 75 87.5 33.3 100 93.8 70 83.3 50 0.79 70
Income
<250 83.3** 75** 87.5** 33.3** 95 100* 70 75 50* 0.79** 70**
>250 95.8 100 100 66.7 100 100 80 66.7 50 0.84 89
CD4 count
<200 91.7 87.5 100 50 100 100 75 66.7 25 0.83 80
200–500 83.3 81.3 87.5 33.3 97.5 100 67.5 75 50 0.79 70
>500 83.3 87.5 93.8 50 95 100 75 66.7 50 0.83 80
Missing 87.5 75 87.5 33.3 100 100 70 83.3 50 0.79 72.5
Time on ART
<12 87.5 84.4 96.9 50 92.5 87.5 70 79.2 37.5 0.84* 74.5
12–48 89.6 87.5 87.5 41.7 95 100 70 70.8 50 0.83 79
>48 83.3 75 87.5 33.3 100 100 75 75 50 0.79 77
Notes: Dimensions for the HAT-QoL include the overall function (OVFXN), life satisfaction (LISAT), health worries (HEAWO), ﬁnancial worries (FINWO), medication
worries (MEDWO), HIV mastery (HIVMA), disclosure worries (DISWO), and provider trust (PROTR). QoL scores from the EQ-5D-3L include EQ-5D Index (EQIND)
and visual analogue scale (VAS).
*p < .05.
**p < .01.
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